West Pharmaceutical Services, Inc. — Form 10-Q Summary
Business Context and Reporting Period
West Pharmaceutical Services, Inc. is a global manufacturer of containment, packaging, drug-delivery, contract-manufacturing, and analytical products serving biologic, generic, pharmaceutical, diagnostic, and medical-device customers. Operations are organized into Proprietary Products and Contract-Manufactured Products. This unaudited filing covers the three and nine months ended September 30, 2019, compared with the corresponding 2018 periods.
Key Financial Metrics
| Metric | Q3 2019 | Q3 2018 | 9M 2019 | 9M 2018 |
|---|---|---|---|---|
| Net sales | $456.1 million | $431.7 million | $1,369.3 million | $1,294.9 million |
| Gross profit | $147.8 million | $135.6 million | $452.5 million | $412.2 million |
| Gross margin | 32.4% | 31.4% | 33.0% | 31.8% |
| Operating profit | $67.3 million | $60.8 million | $218.5 million | $174.5 million |
| Operating margin | 14.8% | 14.1% | 16.0% | 13.5% |
| Net income | $56.3 million | $55.2 million | $177.8 million | $154.9 million |
| Diluted earnings per share | $0.75 | $0.73 | $2.36 | $2.05 |
| Operating cash flow | Not separately provided | Not separately provided | $260.8 million | $215.4 million |
Q3 net sales increased 5.7% year over year, while organic growth was 7.9% excluding currency effects and the South Korean acquisition. Nine-month reported sales increased 5.7%, with organic growth of 9.1%. Foreign currency translation reduced reported sales by $10.6 million in Q3 and $45.3 million for the nine-month period.
- Proprietary Products sales increased 6.2% in Q3 and 4.9% for nine months; organic growth was 8.5% and 8.4%, respectively.
- Contract-Manufactured Products sales increased 4.2% in Q3 and 8.7% for nine months; organic growth was 6.0% and 11.3%, respectively.
- Gross-margin expansion reflected favorable product mix, production efficiencies, and price increases, partly offset by higher overhead costs.
- SG&A was 14.2% of sales in Q3 and 14.9% for nine months, compared with 15.0% and 15.7% in the prior-year periods.
- Effective tax rates were 16.8% in Q3 and 19.8% for nine months, compared with 13.1% and 15.1% in 2018.
Liquidity, Debt, and Capital Allocation
- Cash and cash equivalents were $396.0 million at September 30, 2019, compared with $337.4 million at December 31, 2018.
- Working capital was $669.1 million, up from $610.7 million at year-end 2018.
- Total debt was $195.1 million, compared with $196.1 million at December 31, 2018. The company had $269.9 million of available capacity under its $300.0 million revolving credit facility, after borrowings and letters of credit.
- The company was in compliance with all debt covenants. The principal net-debt-to-modified-EBITDA covenant is 3.5 to 1, with limited acquisition-related flexibility to 4.0 to 1.
- Operating cash flow was $260.8 million; capital expenditures were $88.8 million and the South Korean distributor acquisition used $18.9 million.
- Financing cash uses included $33.3 million of dividends and $83.1 million for repurchase of 800,000 shares. The authorized 2019 repurchase program was completed.
Material Changes and Unusual Items
- The company acquired its South Korean distributor in April 2019 for $18.9 million, contributing $2.0 million of incremental nine-month sales and adding goodwill and customer-relationship intangible assets.
- A voluntary recall of the Vial2Bag product line continued because of potential unpredictable or variable dosing. The company recorded a net provision of $4.9 million for the first nine months, including a $0.9 million net adjustment in Q3, and was working to return the products to market.
- Restructuring charges were $1.8 million in Q3 and $3.8 million for nine months. Management expects the restructuring plan, when completed, to provide approximately $14.0 million of annualized savings.
- A $2.7 million pension settlement charge was recorded after lump-sum payments exceeded the settlement-accounting threshold. Benefit accruals under the U.S. defined benefit plans ceased effective January 1, 2019, except for interest crediting.
- Argentina currency devaluation resulted in a $1.0 million charge in both Q3 and the nine-month period.
- Q3 other expense included $5.1 million of foreign-exchange transaction losses, compared with $2.7 million of foreign-exchange gains in Q3 2018.
- Q3 and nine-month net income benefited from a $1.0 million federal tax-law benefit and stock-based-compensation-related tax benefits of $4.0 million and $9.2 million, respectively.
- ASC 842 lease accounting was adopted January 1, 2019, resulting in September 30 operating lease right-of-use assets of $71.3 million and operating lease liabilities of $73.3 million.
- After quarter-end, the company amended commercial agreements with Daikyo and announced that its ownership interest in Daikyo increased to 49%; management expected no material financial-statement impact.
Outlook and Risks
Management stated that cash on hand, operating cash generation, and available revolver capacity should satisfy foreseeable liquidity needs, including capital expenditures and scheduled debt payments. The filing does not provide a specific full-year revenue or earnings-per-share guidance target.
Principal risks include demand and order-pattern changes, customer product approvals and commercialization, competition and pricing pressure, dependence on critical suppliers and Daikyo, raw-material and petroleum-related costs, production and supply-chain disruptions, foreign-exchange volatility, skilled-labor availability, regulatory and healthcare-policy changes, product quality or recall exposure, and the successful development and approval of new products. The filing reports no material changes to previously disclosed risk factors and no material legal proceedings.
Facts Investors Should Verify
- Whether the Vial2Bag recall has been resolved and whether additional returns, provisions, regulatory actions, or market-reentry costs arise.
- Whether organic sales growth and gross-margin expansion are sustained after adjusting for currency, acquisition effects, pricing, and product mix.
- The remaining cost and timing of the restructuring plan and whether the expected $14.0 million annualized savings are achieved.
- The effect of foreign-exchange movements, particularly the U.S. dollar, euro, yen, and Asian currencies, on sales, margins, and accumulated other comprehensive income.
- Daikyo-related commercial, ownership, supply, royalty, and affiliate-transaction implications following the increase to 49% ownership.
- Capital-allocation priorities after completion of the 2019 share repurchase program, including dividends, acquisitions, capital expenditures, and debt levels.
- Potential variability in reported earnings from pension settlement accounting, tax benefits, restructuring charges, Argentina currency effects, derivatives, and other nonrecurring items.